_petra-next-generation-parp1-selective-inhibitor-azd5305-in-patients-with-brca1-2-palb2-or-rad51c-d-mutations.jpg "PETRA: Next generation PARP1-selective inhibitor AZD5305 in patients with BRCA1 2, PALB2 or RAD51C D mutations from parp Video Screenshot Preview")
GalleryPlay Video:
(Note: The default playback of the video is HD VERSION. If your browser is buffering the video slowly, please play the REGULAR MP4 VERSION or Open The Video below for better experience. Thank you!)
⏲ Duration: 2 min 70 sec
✓ Published: 11-Apr-2022
✓ Published: 11-Apr-2022
Description:
Dr Timothy Yap speaks to ecancer about the PETRA trial that he presented at the AACR 2022 meeting. The trial was a first in class, first in human trial of the next generation PARP1-selective inhibitor AZD5305 in patients with BRCA1/2, PALB2 or RAD51C/D mutations.nnHe reports that the results showed that AZD5305 successfully improved safety and showed promising clinical activity.nnDr Yap believes that this is proof of concept in the clinic for this innovative strategy and that expansion trials ar
Dr Timothy Yap speaks to ecancer about the PETRA trial that he presented at the AACR 2022 meeting. The trial was a first in class, first in human trial of the next generation PARP1-selective inhibitor AZD5305 in patients with BRCA1/2, PALB2 or RAD51C/D mutations.nnHe reports that the results showed that AZD5305 successfully improved safety and showed promising clinical activity.nnDr Yap believes that this is proof of concept in the clinic for this innovative strategy and that expansion trials ar
Share with your friends:
Whatsapp | Viber | Telegram | Line | SMS
Email | Twitter | Reddit | Tumblr | Pinterest
Related Videos
_4th-grade-parp-song.webp "The whole 4th grade practices their special song for the PARP closing assembly during their chorus class.Since their special genre is disco, their song was based on The Bee Gee's hit:")
_koos-van-der-hoeven-parp-remmers.webp "Koos van der Hoeven - PARP-remmers from parp")
_m1-parp-inhibitors-as-monotherapy-in-advanced-prostate-cancer.webp "The aim of this animated video is to provide an understanding of the use of PARP inhibitors as monotherapy in advanced prostate cancer.")
_esmo-2022-latest-in-parp-inhibitors-for-metastatic-prostate-cancer.webp "Dr Neal Shore (Carolina Urologic Research Center, Myrtle Beach, USA), Dr Pasquale Rescigno (Istituto di Candiolo IRCCS (Candiolo Cancer Institute), Candiolo, Italy), Prof Noel Clarke (The Christie NHS Foundation Trusts, Manchester, UK) and Dr Friederike Schlürmann (Centre Hospitalier Universitaire de Brest, Brest, France) discuss the latest in metastatic prostate cancer from ESMO 2022.nnThey discuss the differences in PARP inhibitors in PC and the efficacy of these PARP inhibitors. Prof Noel Cl")
_sabcs-2017-phase-iii-embraca-trial-comparing-talazopari-to-physician39s-choice-of-therapy-meets-primary-endpoint.webp "SABCS 2017: Phase III EMBRACA Trial Meets Primary EndpointnGS6-07. Litton J, Rugo HS, Ettl J, Hurvitz S, et al. EMBRACA: A phase 3 trial comparing talazoparib, an oral PARP inhibitor, to physician's choice of therapy in patients with advanced breast cancer and a germline BRCA mutation.nPresented at the San Antonio Breast Cancer Symposium Press Conference, December 8 - More Info: http://oncoletter.ch")
⏲ 9 min 35 sec ✓ 08-Dec-2017
_tropicana-39parp39.webp "Direction /// Jens & AnnanProd. Company /// Picasso PicturesnExec. Producer /// Inga JohnsonnCharacter Design /// Jens & AnnannAgency /// AMV BBDOnClient /// PepsiConnVFX supervisor /// Bence VargannModelling /// David Kent, Sergei ShabarovnRigging /// Sergei ShabarovnAnimation /// Aurel Duhayon, Juliette CoutelliernSimulation /// Eaton CrousnLighting & Rendering /// Benoit Berthe Siward, Kevin RussellnnCompositing Lead /// Bence VarganCompositing /// Ernesto Herrmann, Arnaud Dumeyni")
_stories-of-innovation-preact.webp "Historically, more than 75% of ovarian cancers would eventually recur, at which point they are not curable. But recent FDA approvals for a new class of oral drugs called parp inhibitors have resulted in significantly improved survival for newly diagnosed ovarian cancer patients.nnHowever, the effectiveness of these treatments is dependent on genetic and tumor mutations. A complex process of multiple genetic and tumor tests, each of which can take weeks to complete, must be completed within fou")
_petra-next-generation-parp1-selective-inhibitor-azd5305-in-patients-with-brca1-2-palb2-or-rad51c-d-mutations.webp "Dr Timothy Yap speaks to ecancer about the PETRA trial that he presented at the AACR 2022 meeting. The trial was a first in class, first in human trial of the next generation PARP1-selective inhibitor AZD5305 in patients with BRCA1/2, PALB2 or RAD51C/D mutations.nnHe reports that the results showed that AZD5305 successfully improved safety and showed promising clinical activity.nnDr Yap believes that this is proof of concept in the clinic for this innovative strategy and that expansion trials ar")
⏲ 2 min 70 sec ✓ 11-Apr-2022
_4th-grade-parp-song.jpg)
_koos-van-der-hoeven-parp-remmers.jpg)
_m1-parp-inhibitors-as-monotherapy-in-advanced-prostate-cancer.jpg)
_esmo-2022-latest-in-parp-inhibitors-for-metastatic-prostate-cancer.jpg)
_sabcs-2017-phase-iii-embraca-trial-comparing-talazopari-to-physician39s-choice-of-therapy-meets-primary-endpoint.jpg)
_tropicana-39parp39.jpg)
_stories-of-innovation-preact.jpg)
![[+]](/images/menu.gif){kind=small}